Market Closed -
Other stock markets
|
Pre-market 07:54:58 am | |||
762.7 USD | +1.13% | 760.4 | -0.30% |
Mar. 18 | AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers | RE |
Mar. 15 | Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time | RE |
Financials (USD)
Sales 2024 * | 41.35B | Sales 2025 * | 51.31B | Capitalization | 687B |
---|---|---|---|---|---|
Net income 2024 * | 10.93B | Net income 2025 * | 15.81B | EV / Sales 2024 * | 16.9 x |
Net Debt 2024 * | 13.51B | Net Debt 2025 * | 7.93B | EV / Sales 2025 * | 13.5 x |
P/E ratio 2024 * |
62.9
x | P/E ratio 2025 * |
42.7
x | Employees | 43,000 |
Yield 2024 * |
0.68% | Yield 2025 * |
0.77% | Free-Float | 99.71% |
Latest transcript on Eli Lilly and Company
1 day | -0.29% | ||
1 week | +3.85% | ||
Current month | +1.19% | ||
1 month | -2.48% | ||
3 months | +31.55% | ||
6 months | +33.50% | ||
Current year | +30.83% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 13-09-30 |
Ruth Gimeno
PSD | President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 64 | 04-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.49% | 18 M€ | +5.16% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 762.7 | +1.13% | 2,521,351 |
24-03-15 | 754.2 | -0.86% | 3,730,053 |
24-03-14 | 760.7 | +0.38% | 2,647,549 |
24-03-13 | 757.8 | +0.38% | 2,357,486 |
24-03-12 | 755 | +2.80% | 2,701,718 |
Delayed Quote Nyse, March 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.83% | 687B | |
+30.96% | 595B | |
+0.01% | 378B | |
+15.18% | 316B | |
+11.39% | 308B | |
+0.78% | 211B | |
-6.09% | 208B | |
-2.92% | 203B | |
-3.72% | 157B | |
-5.94% | 145B |